GRI Bio GRI
NASDAQ GRI
$1.47 +0.01 (+0.68%)
At close: Oct 21, 2026 · 4:00 PM EDT

GRI Bio (GRI) Capital Leases (2020 - 2021)

Updated

GRI Bio (GRI) posted Capital Leases of $146,000 for Q1 2021, down 14.1% from the prior quarter.

Analysis

GRI Bio (GRI) Capital Leases (2020 - 2021) Analysis & Trends

At the end of FY2020, GRI Bio's Capital Leases came in at $170,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 GRI Bio 2.65 Mn -31.63 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 146,000.00
Dec 31, 2020 170,000.00
API Access

GRI Bio Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=GRI&period=max&api_key=YOUR_API_KEY